[go: up one dir, main page]

ES2151597T3 - Composiciones inmunogenicas de polisacaridos estreptococcicos del grupo a y procedimientos. - Google Patents

Composiciones inmunogenicas de polisacaridos estreptococcicos del grupo a y procedimientos.

Info

Publication number
ES2151597T3
ES2151597T3 ES95916479T ES95916479T ES2151597T3 ES 2151597 T3 ES2151597 T3 ES 2151597T3 ES 95916479 T ES95916479 T ES 95916479T ES 95916479 T ES95916479 T ES 95916479T ES 2151597 T3 ES2151597 T3 ES 2151597T3
Authority
ES
Spain
Prior art keywords
group
polisacarids
streptococcic
procedures
immunogenic compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95916479T
Other languages
English (en)
Inventor
Milan S Blake
John B Zabriskie
Joseph Y Tai
Francis Michon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rockefeller University
North American Vaccine Inc
Original Assignee
Rockefeller University
North American Vaccine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rockefeller University, North American Vaccine Inc filed Critical Rockefeller University
Application granted granted Critical
Publication of ES2151597T3 publication Critical patent/ES2151597T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE PROPORCIONA UN NUEVO COMPUESTO INMUNOGENICO Y VACUNA, PROCESOS PARA PRODUCIRLOS Y METODOS DE INMUNIZACION CONTRA INFECCIONES Y TRASTORNOS CAUSADOS POR EL STREPTOCOCCI GRUPO A. LOS COMPUESTOS INCLUYEN POLISACARIDOS ESTREPTOCOCICOS DEL GRUPO A UNIDOS DE FORMA COVALENTE A PROTEINAS O LIPOSOMAS PARA FORMAR CONJUGADOS INMUNOGENICOS. EL METODO DE INMUNIZACION QUE SE DESCRIBE SE BASA EN LA ADMINISTRACION A UN INDIVIDUO DE UNA CANTIDAD INMUNOGENICA DE POLISACARIDOS DEL GRUPO A. ESTOS POLISACARIDOS PUEDEN ADMINISTRARSE COMO UNA VACUNA O POR SI MISMOS, UNIDOS A PROTEINAS O A LIPOSOMAS. ADICIONALMENTE LOS POLISACARIDOS DEL GRUPO A PUEDEN ASOCIARSE CON UN ADYUVANTE. ESTA INVENCION ES DE GRAN UTILIDAD PARA PROTEGER INMUNOGENICAMENTE DE FORMA ACTIVA Y PASIVA A AQUELLOS SECTORES DE LA POBLACION ESPECIALMENTE EN RIESGO DE CONTRAER INFECCIONES POR ESTE ESTREPTOCOCO COMO PUEDEN SER ADULTOS, MUJERES EMBARAZADAS, NIÑOS Y ADOLESCENTES.
ES95916479T 1994-04-21 1995-04-20 Composiciones inmunogenicas de polisacaridos estreptococcicos del grupo a y procedimientos. Expired - Lifetime ES2151597T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/231,229 US5866135A (en) 1994-04-21 1994-04-21 Group A streptococcal polysaccharide immunogenic compositions and methods

Publications (1)

Publication Number Publication Date
ES2151597T3 true ES2151597T3 (es) 2001-01-01

Family

ID=22868303

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95916479T Expired - Lifetime ES2151597T3 (es) 1994-04-21 1995-04-20 Composiciones inmunogenicas de polisacaridos estreptococcicos del grupo a y procedimientos.

Country Status (17)

Country Link
US (2) US5866135A (es)
EP (1) EP0754055B1 (es)
JP (1) JPH09512276A (es)
CN (1) CN1159064C (es)
AT (1) ATE196605T1 (es)
AU (1) AU709797B2 (es)
BR (1) BR9507400A (es)
CA (1) CA2188284C (es)
DE (1) DE69518978T2 (es)
DK (1) DK0754055T3 (es)
ES (1) ES2151597T3 (es)
FI (1) FI118514B (es)
GR (1) GR3034916T3 (es)
NO (1) NO321321B1 (es)
PL (1) PL181037B1 (es)
PT (1) PT754055E (es)
WO (1) WO1995028960A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6153406A (en) * 1993-07-23 2000-11-28 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane protein P2 from Haemophilus influenzae type B
US5866135A (en) * 1994-04-21 1999-02-02 North American Vaccine, Inc. Group A streptococcal polysaccharide immunogenic compositions and methods
US5846547A (en) 1996-01-22 1998-12-08 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US6355255B1 (en) 1998-12-07 2002-03-12 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US6756361B1 (en) * 1997-10-14 2004-06-29 Nabi Enterococcus antigens and vaccines
US6572867B1 (en) * 1998-04-15 2003-06-03 Baxter International Inc. Inhibition of xenoreactive antibodies
MY125387A (en) * 1999-03-19 2006-07-31 Smithkline Beecham Biologicals S A Vaccine
US7256265B2 (en) 1999-12-03 2007-08-14 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
CN101260149B (zh) * 2000-06-20 2016-05-11 魁北克益得生物医学公司 链球菌抗原
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
US20020192205A1 (en) * 2001-05-11 2002-12-19 Francis Michon Immunogenic compositions of low molecular weight hyaluronic acid and methods to prevent, treat and diagnose infections and diseases caused by group A and group C streptococci
WO2003015815A1 (en) * 2001-08-21 2003-02-27 The Brigham And Women's Hospital, Inc. Improved conjugate vaccines
WO2004009770A2 (en) * 2002-07-19 2004-01-29 The Regents Of The University Of California Methods and compositions for modulating agonist-induced downregulation of g protein-coupled receptors
US20040197845A1 (en) * 2002-08-30 2004-10-07 Arjang Hassibi Methods and apparatus for pathogen detection, identification and/or quantification
US7255867B2 (en) * 2002-11-15 2007-08-14 Id Biomedical Corporation Of Quebec Vaccine
US20070184072A1 (en) * 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US7709001B2 (en) * 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
JP5555623B2 (ja) * 2007-06-20 2014-07-23 バクスター・インターナショナル・インコーポレイテッド コンジュゲートワクチン用修飾多糖
EP2045201A1 (en) * 2007-10-02 2009-04-08 M T C - Macchine Trasformazione Carta S.r.l. Rewinding method and rewinding machine that carries out this method
EP2344523B1 (en) * 2008-09-17 2016-02-10 GlaxoSmithKline Biologicals SA Combination gas vaccines and therapeutics
DK2349520T3 (en) 2008-10-27 2016-08-15 Glaxosmithkline Biologicals Sa Purification Procedure for Group A Streptococcus Carbohydrate
JP5344558B2 (ja) 2008-10-31 2013-11-20 国立大学法人 東京医科歯科大学 カチオン性ナノゲルを用いる粘膜ワクチン
CN102203122A (zh) 2008-11-05 2011-09-28 惠氏有限责任公司 用于预防β-溶血链球菌(BHS)疾病的多组分免疫原性组合物
US20130149331A1 (en) * 2011-05-03 2013-06-13 Peng George Wang Rhamnose and forssman conjugated immunogenic agents
WO2013020090A2 (en) * 2011-08-04 2013-02-07 The Regents Of The University Of California STREPTOCOCCAL GLcNAc-LACKING GLYCOPOLYPEPTIDES, CELL WALL CARBOHYDRATES, STREPTOCOCCUS VACCINES, AND METHODS FOR MAKING AND USING THEM
CN106606775A (zh) * 2015-10-27 2017-05-03 格里菲斯大学 脂质体a群链球菌疫苗
PL3678654T3 (pl) 2017-09-07 2024-12-16 Merck Sharp & Dohme Llc Polisacharydy pneumokokowe i ich zastosowanie w immunogennych koniugatach polisacharyd-białko nośnikowe
WO2019143969A1 (en) * 2018-01-18 2019-07-25 Claudio Maldonado Treating microvascular dysfunction

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4695624A (en) * 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
NZ214503A (en) * 1984-12-20 1990-02-26 Merck & Co Inc Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates
US5283185A (en) * 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
FR2682388B1 (fr) * 1991-10-10 1995-06-09 Pasteur Merieux Serums Vacc Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal.
ZA937034B (en) * 1992-09-24 1995-06-23 Brigham & Womens Hospital Group B streptococcus type II and type V polysaccharide-protein conjugate vaccines
US5866135A (en) * 1994-04-21 1999-02-02 North American Vaccine, Inc. Group A streptococcal polysaccharide immunogenic compositions and methods

Also Published As

Publication number Publication date
AU2296795A (en) 1995-11-16
NO964413D0 (no) 1996-10-17
FI118514B (fi) 2007-12-14
PT754055E (pt) 2001-02-28
EP0754055A1 (en) 1997-01-22
DE69518978T2 (de) 2001-03-15
US20050163808A1 (en) 2005-07-28
BR9507400A (pt) 1997-10-07
DK0754055T3 (da) 2000-12-18
GR3034916T3 (en) 2001-02-28
CN1149835A (zh) 1997-05-14
US5866135A (en) 1999-02-02
JPH09512276A (ja) 1997-12-09
NO321321B1 (no) 2006-04-24
ATE196605T1 (de) 2000-10-15
PL181037B1 (pl) 2001-05-31
WO1995028960A1 (en) 1995-11-02
DE69518978D1 (de) 2000-11-02
AU709797B2 (en) 1999-09-09
CN1159064C (zh) 2004-07-28
NO964413L (no) 1996-12-17
FI964189L (fi) 1996-12-18
EP0754055B1 (en) 2000-09-27
US7332173B2 (en) 2008-02-19
PL316906A1 (en) 1997-02-17
CA2188284C (en) 2001-04-17
FI964189A0 (fi) 1996-10-18
CA2188284A1 (en) 1995-11-02

Similar Documents

Publication Publication Date Title
ES2151597T3 (es) Composiciones inmunogenicas de polisacaridos estreptococcicos del grupo a y procedimientos.
PT1187629E (pt) Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
GT200200138A (es) Vacunacion en dosis unica con mycoplasma hyopneumoniae
CY1112851T1 (el) Μεθοδος προληψης ή θεραπειας μολυνσης μ. τuβεrculosis
CY1109286T1 (el) Σκευασμα τυπου φυραματος που περιλαμβανουν διοξειδιο πυριτιου
MX9301706A (es) Composicion de vacuna para el tratamiento de la infeccion por helicobacter.
DK1326636T3 (da) Vaccinesammensætning
ES2162319T3 (es) Uso del agente quelante clioquinol para la fabricacion de una composicion farmaceutica para el tratamiento de la enfermedad de alzheimer.
ATE50260T1 (de) Purinderivate, verfahren zu ihrer herstellung und pharmazeutische zubereitung.
DK0395329T3 (da) Sammensætning i form af et skum indeholdende 5-aminosalicylsyre til intrarektal administration
DE69728380D1 (de) Streptokokken c5a peptidase impfstoff
CY1108147T1 (el) Εμβολιο κατα των σεξουαλικως μεταδιδομενων νοσων
PT1206189E (pt) Formulacoes para vacinas de rotavirus
ES2160601T3 (es) Vacunas de conjugado de polisacaridos de estreptococos del grupo b tipo ii y tipo v-proteina.
ES2137310T3 (es) Vacuna contra una infeccion por streptococcus suis.
BRPI0416376A (pt) composições para a redução da colonização bacteriana e da invasão do snc e métodos de uso destes
NL300188I1 (nl) Acellulair vaccin.
ES2059130T3 (es) Composiciones farmaceuticas que contienen ipriflavona, procedimiento para su preparacion y uso terapeutico relacionado.
ES2136064T3 (es) Vacunas de toxoide de pasteurella multocida.
ES2058100T3 (es) Vacuna combinada.
BR9809381A (pt) Composição de vacina anti-helicobacter compreendendo um adjuvante do tipo th1
BR9809426A (pt) Composição de vacina anti-helicobacter para uso pela via sistêmica subdiafragmática e método de imunização mucosal/parenteral combinado
AR027738A1 (es) Composicion coadyuvante, composiciones de vacunas que incluyen dicha composicion coadyuvante; procedimiento de induccion de inmunorespuestas antigenicas enmamiferos y procedimiento de tratamiento donde se aplican dichas vacunas
Milzer et al. Active immunization of mice with ultraviolet-inactivated lymphocytic choriomeningitis virus vaccine and results of immune serum therapy
AR005730A1 (es) Forma de fanciclovir, procedimiento para prepararla, composiciones farmaceuticas que la contienen y metodo para el tratamiento o profilaxis deinfecciones virales y el uso de dicha forma -fanciclovir monoidrato.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 754055

Country of ref document: ES